TCG Crossover Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
TCG Crossover Management reported a $4.2 bn portfolio of 54 positions to the SEC as of the end of Q2 2026. Its largest positions are ABVX, TNGX, CGON. During the quarter it opened ZAI Lab and Aura Biosciences and exited Fulcrum Therapeutics.
Sections with a free account
What changed this quarter
26 positions with a change (9 new, 2 added to, 9 trimmed, 6 sold); also, 3 entered through an IPO, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedFirst Tracks BiotherapeuticsTRAX1.4% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- ZAI Lab+2.8 ppof portfolioNew— → 2.8%
- Aura Biosciences+1.6 ppof portfolioNew— → 1.6%
- Abivax−7.3%fewer sharesReduced20.6% → 19.2%
- Tango Therapeutics−14%fewer sharesReduced6.3% → 6.8%
- Revolution Medicines−41%fewer sharesReduced1.6% → 1.5%
- Avalo Therapeutics+309%more sharesIncreased0.3% → 1.3%
- Fulcrum Therapeutics−1.0 ppof portfolioSold out1.2% → —
- Biohaven−62%fewer sharesReduced1.1% → 0.6%
- Editas Medicine+0.9 ppof portfolioNew— → 0.9%
- Pharvaris+0.8 ppof portfolioNew— → 0.8%
- InflaRx+0.8 ppof portfolioNew— → 0.8%
- Altimmune+0.7 ppof portfolioNew— → 0.7%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- AbivaxABVX19.2%
- Tango TherapeuticsTNGX6.8%
- CG OncologyCGON6.3%
- Cogent BiosciencesCOGT4.5%
- ImmunovantIMVT4.1%
- Spyre TherapeuticsSYRE4.1%
- Dianthus TherapeuticsDNTH3.9%
- Mirum PharmaceuticalsMIRM3.0%
- ZAI LabZLAB2.8%
- Amylyx PharmaceuticalsAMLX2.7%
- Monte Rosa TherapeuticsGLUE2.7%
- Biocryst PharmaceuticalsBCRX2.6%
- Vor BiopharmaVOR2.5%
- Tyra BiosciencesTYRA2.5%
- Dyne TherapeuticsDYN2.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 54
Q2 2026: 57%
Q2 2026: 9.5%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of May 29, 2026 (medium confidence).
The data, as reported: TCG CROSSOVER MANAGEMENT, LLC (CRD 311718): 7.B private funds: 3 other (gross assets $3.8 bn); 5.D assets by client type: pooled vehicles 100% (of $5.1 bn) · 13F: 30% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Crake Asset Management LLPInvestment firm · $4.2 bn
- Jensen Investment ManagementInvestment firm · $4.1 bn
- Troy Asset ManagementInvestment firm · $4.2 bn
- Contour Asset ManagementInvestment firm · $4.2 bn
- Trian Fund ManagementInvestment firm · $4.2 bn
- Altarock PartnersInvestment firm · $4.2 bn